placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/ mild, moderate, or severe using the Truelove and Witt's criteria. Before treatment there were no differences between the cyclosporin and placebo groups in the number of patients with remission/mild colitis, 14/16 (88%) v 9/10 (90%), and moderate colitis, 2/16 (12%) v 1/10 (10%). During treatment, a remission/mild disease course was present in 15/16 (94%) v 6/10 (60%), p=005 and a moderate disease course in 1/16 (6%) v 4/10 (40%), p=005. It is concluded that patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and from fewer flares of remission/mildly active colitis. These findings suggest that cyclosporin may be of benefit to the colon in patients with ulcerative colitis who are being treated with cyclosporin for primary sclerosing cholangitis. (Gut 1993; 34: 242-246) Ulcerative colitis and primary sclerosing cholangitis (PSC) are chronic disorders of unknown cause which are presumed to be chronic immune inflammatory in nature. Primary sclerosing cholangitis occurs in 1-6% of patients with ulcerative colitisl-3 and, conversely, (Table II) . In comparison, out of 10 patients in the placebo group, six had a remission/mild disease course and four had a moderate disease course during the study. The differences in disease severity during the study were paralleled by a higher mean stool frequency for the placebo group as compared with the cyclosporin group, 2-7 v 1 6 stools/day (Table  II) . None of the patients in either group had severe colitis at entry or developed a severe flare during the study. Classification of the disease course (remission/mild, moderate or severe) and calculation of the mean stool frequency were both based on the highest level of disease activity experienced during the entire study. Patients receiving sulphasalazine at study entry (cyclosporin group 75%, placebo group 90%) continued to take the drug throughout the study and did not reduce the dose. All the patients who experienced disease flares were taking sulphasalazine. The sulphasalazine dose was increased in some of these patients but this increase always occurred after the flare started when the colitis had already been classified as moderately active. No patients required corticosteroid treatment for colitis flares.
ENDOSCOPIC DISEASE ACTIVITY At entry, quiescent or mildly active colitis was seen at endoscopy in 15 of 16 patients in the cyclosporin group and nine of 10 in the placebo group. Follow up endoscopy was performed in many patients but this was not done systematically. Cyclosporin treated patients had 22 follow up endoscopies: 10 at one year; six at two years; four at three years; and two at four years. Placebo treated patients had 12 follow up endoscopies: eight at one year; and four at two years. The overall concordance between the clinical and endoscopic level of severity was 93% (cyclosporin group 97%, placebo group 86%). Because endoscopic follow up was inconsistent, we did not attempt to make an assessment of endoscopic disease activity during the treatment period.
TOXICITY
Side effects occurred in both the cyclosporin and placebo groups but were more common in patients receiving cyclosporin (Table III) . Nephrotoxicity (defined in the study protocol as a serum creatinine >141 imol/I or a reduction in the iothalamate clearance below 70 ml/min) occurred only in the cyclosporin treated group. One patient (6%) had a rise in serum creatinine to 203 iimol/l and none of the patients had an iothalamate clearance less than 70 ml/min. There was a rise in the mean serum creatinine which reached statistical significance after two years and a trend towards a decline in the mean iothalamate clearance in cyclosporin treated patients (Fig 1) . In most cases, however, the magnitude of these changes was not sufficient to qualify as nephrotoxicity. Entry significant differences in the mean systolic or diastolic blood pressures at one and two years when compared with entry for either the cyclosporin or placebo groups. Infections appeared to occur more commonly in the cyclosporin group, although the difference was not statistically significant. Recurrent oral and vaginal yeast infections occurred in two patients receiving cyclosporin and oral thrush occurred in one patient receiving placebo. All three patients responded to temporary withdrawal of the study drug and topical nystatin treatment. One patient receiving cyclosporin developed bacterial cholangitis. Cyclosporin treatment was stopped but the patient continued to deteriorate and died from sepsis and shock in spite of antibiotic treatment.
None of the patients who received cyclosporin developed dysplasia or tumours. In the placebo group one patient underwent colectomy after high grade dysplasia of the colon was found at colonoscopy and another patient developed a cholangiocarcinoma, which resulted in death. Other side effects which occurred only in the cyclosporin group included headaches, tingling and numbness in the extremities, tremor, hirsutism, and gingival hyperplasia. When these cyclosporin specific side effects occurred, there may have been a tendency for the study drug to be disclosed. The number of patients with side effects was small, however (Table III) course of intravenous (IV) cyclosporin (4 mg/kg! day) followed by oral cyclosporin (6-8 mg/kg! day) for six months, and that nine of the 11 responders remained in remission during the follow up period. In contrast, Bianchi Porro26 reported five patients treated with oral cyclosporin (8-5 mg/kg/day) and fi've patients treated with IV cyclosporin (4 mg/kg/day) followed by oral azathioprine in the responders. All five patients receiving oral cyclosporin had a remission but relapse occurred within three months of discontinuing the drug. Three of the five patients treated with IV cyclosporin had a remission and one of these three had a relapse nine months later while receiving azathioprine. The validity of comparing the effects of cyclosporin and placebo on ulcerative colitis in patients who were not randomly admitted to the study or removed from the study on the basis of ulcerative colitis disease activity can be justified as follows. Firstly, although patients were randomly admitted to the study on the basis of severity of liver disease, patients with ulcerative colitis in the placebo and cyclosporin treated groups had similar characteristics, including mean age, sex ratio, mean duration of colitis, extent of colitis, concomitant therapy, and ulcerative colitis disease severity (Tables I-II) . Secondly, the mean duration of treatment before study termination was similar in both groups. This is not surprising since the groups were balanced at study entry for severity of liver disease and cyclosporin was not effective in altering the natural progression of primary sclerosing cholangitis to cirrhosis.6 Our results compare the disease activity at entry with the most severe disease activity experienced during the entire treatment period for each patient. To confirm that differences in treatment duration for individual patients did not affect the analysis, we also compared ulcerative colitis disease activity in the placebo and cyclosporin groups at one year when all patients were still in the study. The ultimate clinical course of the colitis became evident during the first year of the study and there was no difference between the one year analysis and the final analysis (Table II) performed after a mean follow up of 2 8 years in the placebo group and 3-0 years in the cyclosporin group.
Concern about nephrotoxicity has been the major factor limiting more widespread investigational use of cyclosporin in ulcerative colitis. Most patients without renal disease receiving cyclosporin have a 20% or more decline in renal function during the first six months of treatment with little progression thereafter."7 3X These changes are usually reversible within two weeks of stopping the drug. In the two largest studies using cyclosporin for inflammatory bowel disease the incidence of nephrotoxicity was 7-10%. 1 25 In all instances the toxicity was easily reversed by reducing the cyclosporin dose. Patients receiving cyclosporin in our study had a 20% rise in mean serum creatinine and a 14% reduction in mean iothalamate clearance at two years. Only one patient (6%) receiving cyclosporin met our criteria for nephrotoxicity and that patient improved after reducing the dose. These findings suggest that low doses of cyclosporin can be given for prolonged periods to patients with ulcerative colitis with minimal nephrotoxicity.
The incidence of minor infections including thrush and candida vaginitis was slightly higher in patients receiving cyclosporin but the difference was not statistically significant. These infections cleared up after standard treatment and temporary discontinuation of the cyclosporin. One patient died from cholangitis and sepsis. Since cholangitis is a frequent complication of primary sclerosing cholangitis, it is not clear that cyclosporin contributed to this death.
A further concern about treating ulcerative colitis with cyclosporin is the carcinogenic risk in patients who already have an increased incidence of colonic dysplasia and carcinoma. In addition, there is a small risk of developing lymphoma with cyclosporin immunosuppression. Most of the reported cases had associated Epstein-Barr viral infection and occurred during treatment with high doses of cyclosporin in combination with corticosteroids and azathioprine.3839 Our results showed no increase in the incidence of any malignancies in patients receiving cyclosporin, although the mean follow up is only 2-8 years.
In conclusion, patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and fewer flares in patients with remission/mild colitis. Significant cyclosporin toxicity during prolonged treatment is minimal and does not appear to be a limiting factor at this dose of cyclosporin. 
